Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amicus Therapeutics 1 Cedar Brook Drive Cranbury NJ 08512 USA

P: 609-662-2000 F: 609-662-2001

Description:

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.

Key Statistics

Overview:

Market Capitalization, $K 3,569,980
Shares Outstanding, K 258,788
Annual Sales, $ 182,240 K
Annual Net Income, $ -356,390 K
Last Quarter Sales, $ 62,350 K
Last Quarter Net Income, $ -52,490 K
60-Month Beta 1.18
% of Insider Shareholders 2.50%
Float, K 252,318
% Float 97.50%

Growth:

1-Year Return 72.35%
3-Year Return -8.52%
5-Year Return 115.88%
5-Year Revenue Growth 14,837.71%
5-Year Earnings Growth -39.36%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.24 on 11/11/19
Next Earnings Date 11/09/20
Earnings Per Share ttm -1.14
EPS Growth vs. Prev Qtr 42.86%
EPS Growth vs. Prev Year 41.18%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

FOLD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -11.04
Price/Earnings to Growth N/A
Return-on-Equity % -65.53%
Return-on-Assets % -36.94%
Profit Margin % -195.56
Net Margin % N/A
Debt/Equity 0.37
Price/Sales 19.60
Price/Cash Flow N/A
Price/Book 9.89
Book Value/Share 1.39
Interest Coverage -17.86
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar